Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483157 | 0.76 | ALOX5 (0.41) | ALOX5OPRM1OPRD1HDAC1HDAC6 | |
| SCHEMBL24667342 | 0.74 | ALDH1A1 (0.38) | ALOX5OPRM1OPRD1 | |
| SCHEMBL3482612 | 0.74 | ALOX5 (0.39) | ALOX5CTSK | |
| SCHEMBL23872654 | 0.73 | ALOX5 (0.35) | ALOX5OPRM1OPRD1 | |
| SCHEMBL3483135 | 0.73 | ALOX5 (0.41) | ALOX5OPRM1OPRD1HDAC1HDAC6 | |
| SCHEMBL3483427 | 0.71 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL12783366 | 0.71 | ALDH1A1 (0.50) | OPRM1OPRD1 | |
| SCHEMBL3482856 | 0.71 | EPHX1 (0.47) | ALOX5HPGDEPHX1 | |
| SCHEMBL21789735 | 0.70 | MLYCD (0.38) | ALOX5OPRM1OPRD1 | |
| SCHEMBL3483305 | 0.70 | ALOX5 (0.36) | ALOX5EPHX1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | ALOX5 12/4885OPRM1 157/4885OPRD1 57/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | ALOX5 6/4885OPRM1 249/4885OPRD1 77/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | ALOX5 6/4885OPRM1 249/4885OPRD1 77/4885 |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | SLC5A1, SLC5A2, SLC2A9 | ALOX5 3841/4885OPRM1 3271/4885OPRD1 3148/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | ALOX5 6/4885OPRM1 249/4885OPRD1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.